方盛制药: directors' dealings · France · AMF SSE:603998 FR FR · AMF Mcap 4.9Bn€
Explore the full insider trade history of 方盛制药, a listed equity based in France. Shares trade on FR FR, under the authority of AMF. Market capitalisation: €4.9bn. The latest transaction was disclosed on 13 May 2025 — Purchase. Among the most active insiders: 何仕. The full history is accessible without an account.
Financial data FY ended December 2025 · cache
Income statement
Revenue 1.75 Bn€
Gross profit 1.26 Bn€ 72% margin
Net income 306.4 M€ 17.5% margin
Balance sheet & cash
Market cap 4.94 Bn€
Total debt 432.0 M€
Free Cash Flow 282.1 M€
Last declaration on 13 May 2025
Declarations 10 total
Executives ● Purchase22 SSE
413,300 shares
SSE:173000008947685700 · 13 May 2025
Ideal exit: 7 Feb 2026 (T+270) Executives ● Purchase22 SSE
10,000 shares
SSE:173000008534553000 · 11 Feb 2025
Ideal exit: 8 Nov 2025 (T+270) Executives ● Purchase18 SSE
17,400 shares
SSE:173000007715424800 · 3 Jun 2024
Ideal exit: 28 Feb 2025 (T+270) Executives ● Purchase18 SSE
3,000 shares
SSE:173000007702092800 · 30 May 2024
Ideal exit: 24 Feb 2025 (T+270) Executives ● Purchase18 SSE
19,000 shares
SSE:173000007553186780 · 26 Apr 2024
Ideal exit: 21 Jan 2025 (T+270) Executives ● Purchase18 SSE
1,000 shares
SSE:173000007543172000 · 25 Apr 2024
Ideal exit: 20 Jan 2025 (T+270) Executives ● Purchase18 SSE
1,000 shares
SSE:173000007534840540 · 24 Apr 2024
Ideal exit: 19 Jan 2025 (T+270) Executives ● Purchase18 SSE
10,000 shares
SSE:173000007190078370 · 27 Dec 2023
Ideal exit: 22 Sept 2024 (T+270) Executives ● Purchase11 SSE
1,000 shares
SSE:173000007190078340 · 26 Dec 2023
Ideal exit: 21 Sept 2024 (T+270) Executives ● Purchase11 SSE
10,000 shares
SSE:173000007180669820 · 22 Dec 2023
Ideal exit: 17 Sept 2024 (T+270)
